{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:34:51Z","timestamp":1788564891689,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270234"],"award-info":[{"award-number":["82270234"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12185-025-04064-3","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T18:39:32Z","timestamp":1757529572000},"page":"917-921","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sequential intrathoracic injection and intravenous infusion of BCMA CAR-T cells in a patient with relapsed\/refractory primary plasma cell leukemia"],"prefix":"10.1007","volume":"122","author":[{"given":"Wei","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Wai","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sze Fai","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhen","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex H.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"4064_CR1","first-page":"379","volume":"19","author":"JF Yamamoto","year":"2008","unstructured":"Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997\u20132002. Cancer Causes Control. 2008;19:379\u201390.","journal-title":"Cancer Causes Control"},{"key":"4064_CR2","doi-asserted-by":"publisher","first-page":"263485352199938","DOI":"10.1177\/2634853521999389","volume":"14","author":"CP Chaulagain","year":"2021","unstructured":"Chaulagain CP, Diacovo M-J, Van A, Martinez F, Fu C-L, Jimenez Jimenez AM, et al. Management of primary plasma cell leukemia remains challenging even in the era of novel agents. Clin Med Insights Blood Disord. 2021;14:2634853521999389.","journal-title":"Clin Med Insights Blood Disord"},{"key":"4064_CR3","doi-asserted-by":"publisher","first-page":"2254556","DOI":"10.1080\/16078454.2023.2254556","volume":"28","author":"J Guan","year":"2023","unstructured":"Guan J, Ma J, Chen B. Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study. Hematology. 2023;28:2254556.","journal-title":"Hematology"},{"key":"4064_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000210555","volume":"121","author":"Q Peijing","year":"2009","unstructured":"Peijing Q, Yan X, Yafei W, Dehui Z, Zengjun L, Junyuan Q, et al. A retrospective analysis of thirty-one cases of plasma cell leukemia from a single center in China. Acta Haematol. 2009;121:47\u201351.","journal-title":"Acta Haematol"},{"key":"4064_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0059-6","volume":"8","author":"E Katodritou","year":"2018","unstructured":"Katodritou E, Terpos E, Delimpasi S, Kotsopoulou M, Michalis E, Vadikolia C, et al. Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. Blood Cancer J. 2018;8:31.","journal-title":"Blood Cancer J"},{"key":"4064_CR6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/leu.2013.241","volume":"28","author":"P Musto","year":"2014","unstructured":"Musto P, Simeon V, Martorelli MC, Petrucci MT, Cascavilla N, Di Raimondo F, et al. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia. 2014;28:222\u20135.","journal-title":"Leukemia"},{"key":"4064_CR7","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/cncr.31718","volume":"125","author":"R Mina","year":"2019","unstructured":"Mina R, Joseph NS, Kaufman JL, Gupta VA, Heffner LT, Hofmeister CC, et al. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. Cancer. 2019;125:416\u201323.","journal-title":"Cancer"},{"key":"4064_CR8","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR t-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726\u201337.","journal-title":"N Engl J Med"},{"key":"4064_CR9","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1001\/jamaoncol.2024.4879","volume":"10","author":"C Li","year":"2024","unstructured":"Li C, Zhou K, Hu Y, Zou D, Chen L, Chen B, et al. Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: the FUMANBA-1 nonrandomized clinical trial. JAMA Oncol. 2024;10:1681\u20138.","journal-title":"JAMA Oncol"},{"key":"4064_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.346","volume":"11","author":"C Li","year":"2021","unstructured":"Li C, Cao W, Que Y, Wang Q, Xiao Y, Gu C, et al. A phase I study of anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma and plasma cell leukemia. Clin Transl Med. 2021;11:e346.","journal-title":"Clin Transl Med"},{"key":"4064_CR11","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1002\/ajh.27469","volume":"99","author":"Y Qi","year":"2024","unstructured":"Qi Y, Li H, Qi K, et al. Clinical outcomes and microenvironment profiling in relapsed\/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapy. Am J Hematol. 2024;99:2286\u201395.","journal-title":"Am J Hematol"},{"key":"4064_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41408-021-00414-6","volume":"11","author":"SA Tuazon","year":"2021","unstructured":"Tuazon SA, Holmberg LA, Nadeem O, Richardson PG. A clinical perspective on plasma cell leukemia; current status and future directions. Blood Cancer J. 2021;11:23.","journal-title":"Blood Cancer J"},{"key":"4064_CR13","doi-asserted-by":"publisher","first-page":"6384","DOI":"10.1158\/1078-0432.CCR-21-2031","volume":"27","author":"M Zhang","year":"2021","unstructured":"Zhang M, Zhou L, Zhao H, Zhang Y, Wei G, Hong R, et al. Risk factors associated with durable progression-free survival in patients with relapsed or refractory multiple myeloma treated with anti-BCMA CAR T-cell therapy. Clin Cancer Res. 2021;27:6384\u201392.","journal-title":"Clin Cancer Res"},{"key":"4064_CR14","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli PS, Zauderer MG, Rivi\u00e8re I, Solomon SB, Rusch VW, O\u2019Cearbhaill RE, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 2021;11:2748\u201363.","journal-title":"Cancer Discov"},{"key":"4064_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4064_CR16","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1016\/j.chest.2021.09.033","volume":"161","author":"J Moore","year":"2022","unstructured":"Moore J, Mahajan A, Makkar P. A rare case of plasma cell leukemia presenting as dyspnea. Chest. 2022;161:e163\u20137.","journal-title":"Chest"},{"key":"4064_CR17","doi-asserted-by":"crossref","unstructured":"Agarwal A, Klair J, Patolia S, Meena NK. 2015 Intrapleural cisplatin for management of malignant pleural effusion in a patient with plasma cell leucaemia. BMJ Case Rep. 2015:bcr2015210044.","DOI":"10.1136\/bcr-2015-210044"},{"issue":"8","key":"4064_CR18","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1182\/bloodadvances.2024015314","volume":"9","author":"J Gauthier","year":"2025","unstructured":"Gauthier J, Liang EC, Huang JJ, Kimble EL, Hirayama AV, Fiorenza S, et al. Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-na\u00efve adult patients with B-ALL. Blood Adv. 2025;9(8):1861\u201372.","journal-title":"Blood Adv"},{"key":"4064_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100929","volume":"54","author":"S Manier","year":"2022","unstructured":"Manier S, Ingegnere T, Escure G, Prodhomme C, Nudel M, Mitra S, et al. Current state and next-generation CAR-T cells in multiple myeloma. Blood Rev. 2022;54:100929.","journal-title":"Blood Rev"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04064-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04064-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04064-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T08:23:49Z","timestamp":1763713429000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04064-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4064"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04064-3","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"assertion":[{"value":"18 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The ethics approval was given by the Ethics Review Committee of the First Affiliated Hospital of Zhejiang University School of Medicine.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the patient for joining the BCMA CAR-T cell clinical study. Participant signed informed consent regarding publication of this case report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}